GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tci Gene Inc (ROCO:6879) » Definitions » Cash Flow from Financing

Tci Gene (ROCO:6879) Cash Flow from Financing : NT$-50.6 Mil (TTM As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Tci Gene Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the six months ended in Dec. 2023, Tci Gene paid NT$0.0 Mil more to buy back shares than it received from issuing new shares. It received NT$0.0 Mil from issuing more debt. It paid NT$0.0 Mil more to buy back preferred shares than it received from issuing preferred shares. It received NT$0.0 Mil from paying cash dividends to shareholders. It spent NT$46.2 Mil on other financial activities. In all, Tci Gene spent NT$46.2 Mil on financial activities for the six months ended in Dec. 2023.


Tci Gene Cash Flow from Financing Historical Data

The historical data trend for Tci Gene's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tci Gene Cash Flow from Financing Chart

Tci Gene Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Financing
-12.00 - 54.61 535.73 -50.64

Tci Gene Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only - 573.48 -37.75 -1.14 -49.51

Tci Gene Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Tci Gene's Cash from Financing for the fiscal year that ended in Dec. 2023 is calculated as:

Tci Gene's Cash from Financing for the quarter that ended in Dec. 2023 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-50.6 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tci Gene  (ROCO:6879) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Tci Gene's issuance of stock for the six months ended in Dec. 2023 was NT$0.0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Tci Gene's repurchase of stock for the six months ended in Dec. 2023 was NT$0.0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Tci Gene's net issuance of debt for the six months ended in Dec. 2023 was NT$0.0 Mil. Tci Gene received NT$0.0 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Tci Gene's net issuance of preferred for the six months ended in Dec. 2023 was NT$0.0 Mil. Tci Gene paid NT$0.0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Tci Gene's cash flow for dividends for the six months ended in Dec. 2023 was NT$0.0 Mil. Tci Gene received NT$0.0 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Tci Gene's other financing for the six months ended in Dec. 2023 was NT$-46.2 Mil. Tci Gene spent NT$46.2 Mil on other financial activities.


Tci Gene Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Tci Gene's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Tci Gene (ROCO:6879) Business Description

Traded in Other Exchanges
N/A
Address
No. 185-1, Gangqian Rd, 10th FLoor, Neihu District, Taipei, TWN
Tci Gene Inc provides precision preventive medicines in Taiwan. It is the first to introduce the concept of precision preventive medicine with Predict prediction, Prevent prevention, and Personal Treatment personalized health management measures.

Tci Gene (ROCO:6879) Headlines

No Headlines